PharmaEssentia Corporation updated on the Company's IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 following P1101 in Patients with Advanced Solid Tumors to TFDA Current development stage: Application submission/approval/disapproval/each of clinical trials (include interim analysis): The Company received the review opinions on the IND application of the phase I clinical trial of sequential treatment of anti-PD-1 monoclonal antibody new drug P1801 following P1101 in patients with advanced solid tumors from the Taiwan Ministry of Health and Welfare (MOHW) that MOHW was not able to agree to the implementation. The Company will submit the supplementary information as MOHW advised within the timeline. Risks and mitigation measures to be taken by the company upon disapproval of the competent authority: The Company will submit the supplementary information as MOHW advised within the timeline.

Accumulated investment expenditure incurred: In consideration of the future marketing strategy and to protect the rights of the company and investors, no public disclosure will be made for the time being. Upcoming development plan:Phase I clinical trial. Estimated date of completion: Subject recruitment for this trial consists of the following phases: ?Dose Escalation Phase?

and ?Dose Expansion Phase.? The enrollment for all groups is expected to be completed in 2027 following the ?Dose Escalation Phase? completed in 2025.

The timeline will be adjusted according to the actual progress of the clinical trial, and disclosure will be made upon the progress of the study according to the regulations. Market situation: According to the GLOBOCAN 2020 released by the International Agency for Research on Cancer (IARC), there were 19,292,789 new cancer patients and 9,958,133 cancer deaths in 2020 worldwide. Ropeginterferon alfa-2b is approved to treat adult patients with Polycythemia Vera (PV) in the European Union, Taiwan, Switzerland, Israel, South Korea, Macao, United States, Japan, Bahrain, Qatar, and the United Arab Emirates.